US Pre-Market SEC Filings Roundup — February 22, 2026

23-02-2026

23-02-2026

Domino's Pizza Inc filed an 8-K on February 23, 2026 (AccNo: 0001193125-26-062313), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits) as part of its financial results disclosure. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing summary. This appears to be a standard earnings-related 8-K with attached exhibits likely containing press release details.

23-02-2026

Atomera Inc filed a Form 8-K on February 23, 2026, under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), indicating disclosure of unspecified other events with attached exhibits. No specific details on the events, transactions, financial metrics, or quantitative data are provided in the filing summary. This appears to be a multi-item, potentially voluntary informational filing with file size of 297 KB.

23-02-2026

MoonLake Immunotherapeutics filed a Form 8-K on February 23, 2026 (AccNo: 0001213900-26-018967), reporting multiple items including Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing indicating several material corporate developments, but specific transaction details, financial metrics, dollar values, and impacts are NOT_DISCLOSED. No quantitative data, period-over-period comparisons, or named entities beyond the filer are provided.

23-02-2026

CenterPoint Energy Inc. filed an 8-K on February 23, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, or impacts are provided in the filing summary. Sector information is not specified.

23-02-2026

AppTech Payments Corp. filed an 8-K on February 23, 2026, reporting under Item 1.01 entry into a Material Definitive Agreement. Item 9.01 includes Financial Statements and Exhibits. No specific details on the agreement, transaction value, financial impacts, or other metrics are disclosed.

23-02-2026

Barinthus Biotherapeutics plc filed an 8-K on 2026-02-23 reporting under Item 1.01 entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No specific transaction details, financial metrics, positive or negative impacts, or quantitative data are provided in the filing summary.

23-02-2026

Artificial Intelligence Technology Solutions Inc. filed an 8-K on February 23, 2026, reporting under Item 3.03 (Material Modifications to Rights of Security Holders), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific details on the modifications, amendments, disclosures, or exhibits are provided, resulting in no quantifiable positive or negative metrics. This multi-item filing appears informational without disclosed financial or operational impacts.

23-02-2026

CENTENE CORP filed an 8-K on 2026-02-23 under Item 7.01 Regulation FD Disclosure, a voluntary filing to disclose material nonpublic information in compliance with Regulation FD. No specific financial metrics, transactions, guidance, or operational details are mentioned in the filing summary. Filing size is 154 KB with Accession Number 0001071739-26-000052.

23-02-2026

BullFrog AI Holdings, Inc. filed an 8-K on 2026-02-23 disclosing under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, with potential transfer of listing. Item 9.01 reports financial statements and exhibits. No quantitative financial metrics, transaction values, or further details on the delisting rationale or impacts are disclosed.

23-02-2026

Entravision Communications Corp filed an 8-K on February 23, 2026 (AccNo: 0001193125-26-061961), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on positions affected, names, reasons for change, timing, or any quantitative metrics are disclosed.

23-02-2026

K2 Capital Acquisition Corp filed an 8-K on 2026-02-23 under Item 8.01 Other Events announcing a Merger/Acquisition. No specific deal structure, parties involved, valuation, financial terms, or other quantitative details are disclosed in the provided filing metadata. Sector is not specified, and no positive or negative metrics are mentioned.

23-02-2026

Illinois Tool Works Inc filed a multi-item 8-K on February 23, 2026, disclosing under Item 1.01 entry into a material definitive agreement, under Item 1.02 termination of a material definitive agreement, under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, and Item 9.01 financial statements and exhibits. The filing reflects both new commitments and the end of prior ones alongside additional financial obligations. No specific transaction details, values, or impacts are disclosed.

23-02-2026

The company filed an 8-K on 2026-02-23 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers related to an officer change. Item 8.01 reports other events. No specific details on affected positions, names, reasons, or quantitative impacts are disclosed.

23-02-2026

Carlyle Secured Lending, Inc. filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and other events under Item 8.01. No specific details on the affected position, individuals involved, reasons for the change, or any quantitative metrics are disclosed. No positive or negative performance metrics are mentioned.

23-02-2026

Digi Power X Inc. filed an 8-K on February 23, 2026 (AccNo: 0001213900-26-018930, size 221 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary disclosure likely sharing material non-public information publicly, with exhibits attached, but specific content, financial metrics, or transaction details are NOT_DISCLOSED. No quantitative data, guidance changes, or directional impacts are evident from the filing metadata.

• ·AccNo: 0001213900-26-018930
• ·File size: 221 KB
• ·Sector: not specified

23-02-2026

Kinder Morgan, Inc. filed an 8-K on February 23, 2026, under Item 7.01 Regulation FD Disclosure. No specific core event, financial metrics, transactions, guidance changes, or other quantitative details are disclosed in the provided filing information. This is a voluntary disclosure with no mentioned positive or negative performance indicators.

23-02-2026

Shorepower Technologies Inc. filed an 8-K on February 23, 2026, announcing completion of an acquisition or disposition of assets (Item 2.01), unregistered sales of equity securities (Item 3.02), changes in control of the registrant (Item 5.01), departures/elections/appointments of directors and officers with compensatory arrangements (Item 5.02), and amendments to articles of incorporation or bylaws (Item 5.03). Item 9.01 includes financial statements and exhibits. No specific deal terms, financial metrics, parties involved, or quantitative impacts are disclosed.

23-02-2026

Enertopia Corp. filed an 8-K on February 23, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific transactions, financial metrics, period-over-period comparisons, or other quantitative details are disclosed in the filing summary. This appears to be an informational disclosure with attached exhibits, but content details are not provided.

23-02-2026

Miluna Acquisition Corp filed an 8-K on 2026-02-23 disclosing information under Item 5.02 regarding departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No specific names, dates, terms, financial details, or transaction-related information are provided in the filing summary. No quantitative metrics, positive or negative changes, or merger/acquisition details are mentioned.

23-02-2026

Freshpet, Inc. filed an 8-K on February 23, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but provides no specific quantitative metrics, period-over-period comparisons, or guidance details in the available summary. No positive or negative financial changes are detailed.

23-02-2026

Ovintiv Inc. filed an 8-K on February 23, 2026, disclosing under Item 1.01 its entry into a material definitive agreement. Item 9.01 provides for financial statements and exhibits, likely including the agreement document. No specific terms, values, financial impacts, or other metrics are disclosed in the available filing summary.

23-02-2026

Gilead Sciences, Inc. filed an 8-K on 2026-02-23 reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. No details on the nature of the agreement, transaction value, financial impacts, or other quantitative metrics are disclosed. This is a multi-item mandatory filing for Items 1.01 and 9.01 with Item 7.01 often accompanying forward-looking disclosures.

• ·AccNo: 0001104659-26-018314

23-02-2026

Easterly Government Properties, Inc. filed an 8-K on 2026-02-23 disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, revenue, earnings, guidance, period-over-period comparisons, or other quantitative data are disclosed in the provided filing information. This is an informational filing for financial results with no detailed performance indicators available.

23-02-2026

Zura Bio Ltd filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officers, reasons for change, or compensatory arrangements are provided in the available information. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

23-02-2026

PENN Entertainment, Inc. filed a Form 8-K on 2026-02-23 disclosing entry into a material definitive agreement (Item 1.01), departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements (Item 5.02), Regulation FD disclosure (Item 7.01), and financial statements and exhibits (Item 9.01). This is a multi-item filing with no specific details on the agreement, personnel changes, disclosures, or financial impacts provided in the summary. No quantitative metrics, positive or negative changes, or period-over-period comparisons are mentioned.

23-02-2026

ImmunityBio, Inc. filed an 8-K on February 23, 2026 (AccNo: 0001326110-26-000025), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, period-over-period comparisons, revenue, earnings, guidance, or other quantitative data are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed results provided.

23-02-2026

Stepan Co filed an 8-K on February 23, 2026, reporting under Item 2.05 costs associated with exit or disposal activities, under Item 7.01 a Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing indicating material restructuring or disposal-related costs alongside voluntary material information disclosure. No specific dollar amounts, financial metrics, period-over-period changes, or other quantitative details are disclosed.

23-02-2026

Coronado Global Resources Inc. filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No specific details on the key position affected, appointment or resignation status, reasons, timing, or any quantitative metrics are provided. No positive or negative governance implications, board outcomes, or succession signals can be assessed due to lack of disclosed information.

23-02-2026

Foghorn Therapeutics Inc. filed an 8-K on 2026-02-23 disclosing officer or director changes, including departures, elections, appointments, or compensatory arrangements under Item 5.02, other events under Item 8.01, and financial statements/exhibits under Item 9.01. No specific details on the affected positions, names, reasons for changes, timing, or any quantitative metrics such as compensation amounts or share counts are explicitly stated. This is an informational filing with all key leadership change details NOT_DISCLOSED.

23-02-2026

Vanda Pharmaceuticals Inc. filed an 8-K on February 23, 2026, disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or the content of the exhibits are provided in the filing summary. No financial metrics, transactions, or quantitative data are mentioned.

23-02-2026

Axsome Therapeutics, Inc. filed a Form 8-K on 2026-02-23 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without quantified metrics.

23-02-2026

ADC Therapeutics SA filed a Form 8-K on February 23, 2026, disclosing entry into a material definitive agreement under Item 1.01 and unregistered sales of equity securities under Item 3.02, with exhibits under Item 9.01. No specific details on the agreement terms, transaction value, share counts, or financial impacts are provided in the filing summary. This represents a multi-item mandatory disclosure with no quantitative metrics or performance comparisons disclosed.

23-02-2026

Armata Pharmaceuticals, Inc. filed a Form 8-K on 2026-02-23 (AccNo: 0001104659-26-018333, size: 222 KB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the disclosed information, transactions, financial metrics, or events provided in the summary. No quantitative data, positive or negative metrics, or period-over-period comparisons are mentioned.

23-02-2026

Veris Residential, Inc. filed an 8-K on February 23, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is a multi-item filing announcing financial results with exhibits attached.

23-02-2026

United Homes Group, Inc. filed a Form 8-K on 2026-02-23 reporting entry into a material definitive agreement under Item 1.01, departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements under Item 5.02, along with Regulation FD disclosure under Item 7.01 and financial statements/exhibits under Item 9.01. No quantitative financial metrics, transaction values, positive or negative performance indicators, or period-over-period comparisons are disclosed. This is a multi-item informational filing with no specified directional impacts.

23-02-2026

ProCap Financial, Inc. filed an 8-K on February 23, 2026 (AccNo: 0001493152-26-007682, Size: 277 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing likely involving voluntary disclosure of material information to comply with Regulation FD, with exhibits attached. No quantitative financial metrics, transactions, guidance, or specific events are disclosed in the provided filing details.

• ·Filing date: 2026-02-23
• ·Accession Number: 0001493152-26-007682
• ·File size: 277 KB

23-02-2026

Dominion Energy, Inc. filed an 8-K on February 23, 2026, under Item 2.02 reporting results of operations and financial condition, and Item 9.01 for financial statements and exhibits. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no detailed performance data available.

23-02-2026

Resolute Holdings Management, Inc. filed a Form 8-K on February 23, 2026, disclosing under Item 1.01 entry into a new material definitive agreement, under Item 1.02 termination of a prior material definitive agreement, and under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement. No specific details on the nature of the agreements, transaction values, parties involved, or financial terms were provided. This multi-item filing signals significant contractual changes including both a new commitment and termination of an existing one, but lacks quantification of impacts.

23-02-2026

AMC Entertainment Holdings, Inc. filed an 8-K on February 23, 2026, reporting under Item 2.04 a triggering event that accelerates or increases a direct financial obligation or an obligation under an off-balance sheet arrangement, alongside Item 8.01 for other events and Item 9.01 for financial statements and exhibits. This multi-item filing indicates a potentially material credit or liquidity event, but no specific details, dollar values, or quantitative impacts are disclosed. No positive or offsetting metrics are mentioned.

23-02-2026

Real Asset Acquisition Corp. filed an 8-K on February 23, 2026, disclosing entry into a material definitive agreement under Item 1.01, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01 related to a merger/acquisition event. No specific deal structure, parties, valuation, financial metrics, synergies, or impacts were disclosed in the provided filing summary. No quantitative data, comparisons, or scheduled events were mentioned.

23-02-2026

Gibraltar Industries, Inc. filed a Form 8-K on February 23, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, financial statements, exhibits, transactions, metrics, or impacts were disclosed in the provided filing information. This appears to be an informational disclosure with no quantitative data or directional implications mentioned.

23-02-2026

Genprex, Inc. filed a Form 8-K on February 23, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information.

23-02-2026

GameSquare Holdings, Inc. filed a Form 8-K on February 23, 2026, disclosing multiple events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 3.03 (Material Modifications to Rights of Security Holders), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction details, financial metrics, or quantitative impacts provided. No positive or negative performance metrics are disclosed.

23-02-2026

Outdoor Holding Co filed an 8-K on February 23, 2026, reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transactions, events, positive or negative changes, or quantitative data are disclosed in the filing summary provided. This is a multi-item informational filing with no detailed content available for analysis.

23-02-2026

News Corp filed a Form 8-K on February 23, 2026, disclosing Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01. This is a multi-item filing with no specific details on the nature of the events or exhibits provided in the summary. No financial metrics, transactions, or impacts are mentioned.

23-02-2026

CULP INC filed an 8-K on 2026-02-23 reporting under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, along with transfer of listing implications. Item 7.01 discloses Regulation FD information, and Item 9.01 lists financial statements and exhibits. No financial metrics, transaction values, or period-over-period comparisons were disclosed.

23-02-2026

Borealis Foods Inc. filed a Form 8-K on February 23, 2026 (AccNo: 0001213900-26-019022), reporting solely under Item 8.01 Other Events. No specific details of the event, financial metrics, transactions, or quantitative data are disclosed in the provided filing information. This is a single-item voluntary disclosure with no mentioned positive or negative impacts.

23-02-2026

Perpetua Resources Corp. filed an 8-K on February 23, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, guidance, or quantitative data are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance indicators.

23-02-2026

Candel Therapeutics, Inc. filed an 8-K on February 23, 2026, disclosing entry into a material definitive agreement under Item 1.01, other events under Item 8.01, and financial statements and exhibits under Item 9.01. No specific details on the agreement, transaction value, financial impacts, or events were provided in the filing summary. This is a multi-item mandatory disclosure with no quantitative metrics or directional indicators disclosed.

23-02-2026

ALT5 Sigma Corp filed a Form 8-K on February 23, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, any financial statements, exhibits, transactions, metrics, or impacts are disclosed. This appears to be an informational filing without quantified positive or negative developments.

23-02-2026

Strategy Inc filed a Form 8-K on February 23, 2026, reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). No specific details, financial metrics, transactions, or events are disclosed in the provided filing information.

23-02-2026

Peabody Energy Corp filed an 8-K on February 23, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transactions, events, or quantitative data are disclosed in the filing summary. This appears to be a voluntary disclosure of material information with attached exhibits.

23-02-2026

Verisk Analytics, Inc. filed a Form 8-K on February 23, 2026, reporting entry into a material definitive agreement under Item 1.01, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This is a multi-item filing with no specific details on the agreement, transaction terms, financial impacts, or disclosures provided in the summary. No quantitative metrics, positive or negative changes, or period-over-period comparisons are disclosed.

23-02-2026

GeneDx Holdings Corp. filed an 8-K on February 23, 2026 (AccNo: 0001818331-26-000014), reporting under Item 2.02 Results of Operations and Financial Condition, with Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, guidance, or other financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed quantitative data available.

23-02-2026

Getty Images Holdings, Inc. filed an 8-K on February 23, 2026, disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or contents of the exhibits are provided. This appears to be an informational filing with no quantified financial metrics or directional impacts disclosed.

23-02-2026

ASP Isotopes Inc. filed a Form 8-K on February 23, 2026 (AccNo: 0001477932-26-000963), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the disclosure content, financial metrics, transactions, or events are provided in the filing summary. Critical information such as core events, numerical data, or impacts is NOT_DISCLOSED.

23-02-2026

Transcode Therapeutics, Inc. filed an 8-K on February 23, 2026, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific core events, transactions, financial metrics, or quantitative details are disclosed in the filing summary. This appears to be a voluntary disclosure with attached exhibits, but content details are NOT_DISCLOSED.

23-02-2026

Atara Biotherapeutics, Inc. filed a Form 8-K on 2026-02-23 reporting under Item 1.01 entry into a material definitive agreement, under Item 3.02 unregistered sales of equity securities, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. This is a multi-item mandatory disclosure filing with no specific transaction details, dollar values, share counts, financial metrics, or period-over-period comparisons provided. No positive or negative metrics are disclosed, preventing assessment of financial impacts or strategic outcomes.

23-02-2026

Service Properties Trust filed an 8-K on February 23, 2026, under Item 8.01 Other Events. No specific details regarding the event, financial metrics, transactions, or impacts are disclosed in the filing summary provided. No positive, negative, or flat metrics are mentioned.

23-02-2026

Select Water Solutions, Inc. filed a Form 8-K on February 23, 2026 (AccNo: 0001104659-26-018372, Size: 491 KB), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely involving voluntary disclosure of material nonpublic information and other events, with exhibits attached. No specific core events, financial metrics, positive or negative changes, transactions, or quantitative data are disclosed in the provided filing information.

23-02-2026

Lakeland Industries Inc filed an 8-K on February 23, 2026 (AccNo: 0001193125-26-062550), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on affected positions, appointment/resignation status, reasons, or quantitative metrics are disclosed in the provided information.

23-02-2026

Fortress Biotech, Inc. filed an 8-K on February 23, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 8.01 reports other events, and Item 9.01 lists financial statements and exhibits. No specific transaction values, financial impacts, or quantitative metrics are disclosed.

23-02-2026

BioNexus Gene Lab Corp filed an 8-K on February 23, 2026 (AccNo: 0001477932-26-000964, Size: 176 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, financial statements, or exhibits are disclosed. This is a multi-item informational filing with no quantified metrics or directional impacts provided.

23-02-2026

OFF THE HOOK YS INC. filed an 8-K on February 23, 2026 (AccNo: 0001493152-26-007690, Size: 259 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing involving a voluntary disclosure of information to comply with Regulation FD, with unspecified exhibits attached. No financial metrics, transactions, guidance, or other quantitative details are disclosed in the provided filing information.

23-02-2026

VisionWave Holdings, Inc. filed an 8-K on 2026-02-23 disclosing entry into a Material Definitive Agreement under Item 1.01, with Financial Statements and Exhibits attached under Item 9.01. This is a multi-item filing with no specific transaction details, dollar values, parties, or financial impacts provided in the summary. No quantitative metrics, positive or negative changes, or period-over-period comparisons were disclosed.

23-02-2026

OptimumBank Holdings, Inc. filed a Form 8-K on February 23, 2026, reporting under Item 8.01 Other Events, which covers material events not specified elsewhere, and Item 9.01 Financial Statements and Exhibits, indicating attachments are included. No specific details on the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the filing summary. This appears to be a multi-item informational filing with no quantified positive or negative impacts provided.

• ·AccNo: 0001493152-26-007689
• ·File Size: 229 KB

23-02-2026

Gossamer Bio, Inc. filed an 8-K on February 23, 2026, under Item 8.01 Other Events. No specific details on the core event, transaction, financial impacts, or quantitative metrics are disclosed in the provided filing summary. This is a single-item voluntary disclosure with no mentioned positive or negative metrics.

23-02-2026

Avidity Biosciences, Inc. filed a Form 8-K on February 23, 2026 (AccNo: 0001193125-26-062537, Size: 174 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the events, transactions, financial metrics, or exhibits provided in the summary. No positive, negative, or flat performance metrics are disclosed.

23-02-2026

Pelican Acquisition Corp filed an 8-K on February 23, 2026 (AccNo: 0001829126-26-001553), disclosing information under Item 7.01 Regulation FD Disclosure and providing exhibits under Item 9.01 Financial Statements and Exhibits, related to a merger/acquisition event. No specific deal structure, parties, valuation, financial metrics, synergies, or timelines were explicitly stated in the provided filing summary. Sector details are not specified.

23-02-2026

BITMINE IMMERSION TECHNOLOGIES, INC. filed a Form 8-K on February 23, 2026 (AccNo: 0001493152-26-007694, Size: 756 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing involving voluntary Regulation FD compliance and attachment of exhibits. No specific core event, financial metrics, transactions, or other details are disclosed in the provided filing information.

23-02-2026

Ultragenyx Pharmaceutical Inc. filed a Form 8-K on February 23, 2026, under Item 8.01 reporting Other Events. No specific details regarding the nature of the event, financial metrics, transactions, or impacts are disclosed in the provided filing information.

23-02-2026

BrightSpire Capital, Inc. filed a Form 8-K on February 23, 2026, reporting under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, Item 8.01 other events, and Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific transaction details, dollar values, or quantitative impacts disclosed in the provided information. No positive or negative metrics, period-over-period comparisons, or guidance changes are mentioned.

23-02-2026

Fulton Financial Corp filed a Form 8-K on 2026-02-23 under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details on events, transactions, financial metrics, or performance comparisons are disclosed in the provided filing information. This is a multi-item informational filing with no quantified positive or negative impacts reported.